A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of MC-1 on the combined incidence of
cardiovascular death and nonfatal myocardial infarction (MI) up to and including 30 days
following coronary artery bypass graft (CABG) surgery compared with placebo.